ArticlemBio2018
The Genome of the Human Pathogen
Article in mBio, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Invasive Wickerhamomyces anomalus Infections among Injecting Drug Users, France, 2012-2024Emerging infectious diseases · 2026Article
- Parasex generates highly recombinant progeny in Candida albicans with increased virulence.Nature microbiology · 2026Article
- Distinct properties of human pathogenicmSystems · 2026Article
- Targeted loss of heterozygosity in Candida albicans using CRISPR-Cas9 reveals the functional impact of allelic variation.Genetics · 2025Article
- Strain background interacts with chromosome 7 aneuploidy to determine commensal and virulence phenotypes in Candida albicans.PLoS genetics · 2025Article
- The impact of phenotypic heterogeneity on fungal pathogenicity and drug resistance.FEMS microbiology reviews · 2025Review
- Uncovering the role of mitochondrial genome in pathogenicity and drug resistance in pathogenic fungi.Frontiers in cellular and infection microbiology · 2025Review
- How does evolution work in superabundant microbes?Trends in microbiology · 2024Review
- Evolution and strain diversity advance exploration ofmSphere · 2024Review
- Genome Analysis of a Newly Discovered Yeast Species,Journal of fungi (Basel, Switzerland) · 2024Article
- Genomic epidemiology of antifungal resistance in human and avian isolates ofFrontiers in veterinary science · 2024Article
- Genotypic diversity and unrecognized antifungal resistance among populations of Candida glabrata from positive blood cultures.Nature communications · 2023Article
- Genetic Diversity of Human Fungal Pathogens.Current clinical microbiology reports · 2023Article
- Genotypic diversity and unrecognized antifungal resistance among populations of Candida glabrata from positive blood cultures.Research square · 2023Article
- Antifungal Drug Concentration Impacts the Spectrum of Adaptive Mutations in Candida albicans.Molecular biology and evolution · 2023Article
- CRISPR-Cas9 Editing Induces Loss of Heterozygosity in the Pathogenic Yeast Candida parapsilosis.mSphere · 2022Article
- Article
- Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole.G3 (Bethesda, Md.) · 2022Article
- Multiple Stochastic Parameters Influence Genome Dynamics in a Heterozygous Diploid Eukaryotic Model.Journal of fungi (Basel, Switzerland) · 2022Article
- Mitogenomics and mitochondrial gene phylogeny decipher the evolution of Saccharomycotina yeasts.Genome biology and evolution · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The opportunistic fungal pathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.